| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q3 2025 | 2 | 53,189 | STOK, XBI | 13F-HR | 10/29/2025 | 000112329225000594 |
| Q2 2025 | 2 | 37,097 | STOK, XBI | 13F-HR | 7/30/2025 | 000112329225000327 |
| Q1 2025 | 2 | 46,062 | STOK, XBI | 13F-HR | 5/6/2025 | 000112329225000200 |
| Q4 2024 | 2 | 76,327 | STOK, XBI | 13F-HR | 2/5/2025 | 000112329225000035 |
| Q3 2024 | 2 | 109,623 | STOK, XBI | 13F-HR | 10/23/2024 | 000112329224000318 |
| Q2 2024 | 2 | 146,654 | STOK, XBI | 13F-HR | 8/5/2024 | 000112329224000211 |
| Q1 2024 | 2 | 195,149 | STOK, XBI | 13F-HR | 4/26/2024 | 000112329224000117 |
| Q4 2023 | 2 | 76,124 | STOK, XBI | 13F-HR | 2/6/2024 | 000112329224000017 |
| Q3 2023 | 2 | 57,031 | STOK, XBI | 13F-HR | 11/6/2023 | 000112329223000136 |
| Q2 2023 | 4 | 230,310 | STOK, AKRO, ATVI, XBI | 13F-HR | 8/3/2023 | 000112329223000090 |
| Q1 2023 | 4 | 247,473 | AKRO, STOK, ATVI, XBI | 13F-HR | 5/15/2023 | 000112329223000055 |
| Q4 2022 | 4 | 314,404 | AKRO, STOK, ATVI, XBI | 13F-HR | 2/7/2023 | 000156761923001995 |
| Q3 2022 | 4 | 354,309 | STOK, AKRO, ATVI, XBI | 13F-HR | 11/7/2022 | 000156761922019234 |
| Q2 2022 | 4 | 238,987 | STOK, AKRO, ATVI, XBI | 13F-HR | 8/2/2022 | 000156761922014738 |
| Q1 2022 | 4 | 375,563 | STOK, AKRO, ATVI, XBI | 13F-HR | 4/22/2022 | 000156761922008844 |
| Q4 2021 | 5 | 451,947 | STOK, AKRO, ATVI, XBI | 13F-HR | 1/27/2022 | 000156761922001885 |
Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each security where the latest filing since 12/18/2024 is a 13D, newest first.
| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||||
|
Stoke Therapeutics, Inc.
13D/A
STOK · 86150R107
|
4.1% |
8/26/2025
Event 8/22/2025
|
||||
| Blue Horizon Enterprise Ltd | 3.6% | |||||
| Ezbon International Ltd | 0.5% | |||||
| Montrago Trustees Ltd | 4.1% | |||||
| Skorpios Trust | 4.1% | |||||